Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.

S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

Sign up to save your podcasts

S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

More shows like OncLive® On Air

Hematologic Oncology Update

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

The New Yorker Radio Hour

ASCO Daily News

The Daily

OncoPharm

ASCO Guidelines

Lung Cancer Considered

Oncology Today with Dr Neil Love

CCO Oncology Podcast

The Ezra Klein Show

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions